



## Novacyt Named in Deloitte Technology Fast 50

**Paris, France and Cambridge, UK – 26 November, 2015** – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, has been named in the Deloitte Technology Fast 50 in France.

Novacyt today announced that it is ranked in the Deloitte In Extenso Fast 50 - which rewards high growth technology companies in France - due to its increase in revenue of 412% between 2011 and 2014. The Deloitte In Extenso Technology Fast 50 is one of France's foremost technology awards, celebrating innovation and sponsorship.

Novacyt expects to continue its high revenue growth through international market expansion into new markets such as China through its significant partnership with global company, Leica Biosystems. The Company is looking at other growth opportunities in significant geographical markets and other market segments that will benefit from its proprietary NOVAprep® technology platform.

Novacyt received its award in Paris on the 25 November.

Graham Mullis, Group CEO of Novacyt, commented:

*"We are delighted to have been recognised for this prestigious award. Since the merger between Novacyt and Lab21, we have made excellent commercial and operational integration progress. The combined company continues to show a significant increase in revenue as we expand into new markets, and at the same time, we are developing new opportunities for the NOVAprep® technology. I look forward to updating shareholders of our progress."*

Laurent Halfon, Partner responsible for Technology Fast 50 at Deloitte, commented:

*"A measure of confidence among investors and the market, the Deloitte In Extenso Technology Fast 50 shows the dynamism and capacity for innovation of French companies. We are convinced that these technology companies will be tomorrow's spearheads of our economy and the catalysts of a dynamic of growth which creates jobs and value."*

**- Ends -**



## About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NOVAprep® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: [www.novacyt.com](http://www.novacyt.com)



## About the Technology Fast 50 program

The Technology Fast 50 program began in 1995 in San Jose, California, heart of Silicon Valley, and then extended in the United States, the United Kingdom, Canada, Netherlands, Israel and France. It is now present in more than 40 countries and regions in the world. It was created to highlight the remarkable contribution of technology companies to the growth of the economy.

Deloitte has also developed three continental awards:

Europe, Middle East and Africa: Fast 500 EMEA

North America: Fast 500 North America

Asia Pacific: Fast 500 Asia Pacific.

For more information: [www.fast50france.com](http://www.fast50france.com)

## About Deloitte

Deloitte refers to one or more member firms of Deloitte Touche Tohmatsu Limited, a private company limited by guarantee under English company law, and its network of independently incorporated firms and legally separate entities. For more information on the legal structure of Deloitte Touche Tohmatsu Limited and its member firms, visit [www.deloitte.com/about](http://www.deloitte.com/about) . In France, Deloitte SAS is the member firm of Deloitte Touche Tohmatsu Limited, and professional services are provided by its subsidiaries and affiliates.

© 2015 Deloitte SAS

For more information: [www.Deloitte.fr](http://www.Deloitte.fr)



**Contacts:**

**International media and investor enquiries:**

Tony Stephenson

Exitus Communications

+44 (0) 7899 796655

[tony@exituscommunications.co.uk](mailto:tony@exituscommunications.co.uk)

**French Investor & Media**

Emmanuel Huynh

Newcap

+33 (0) 1 44 71 94 95

[novacyt@newcap.fr](mailto:novacyt@newcap.fr)

**NOVACYT**

Graham Mullis

Chief Executive Officer

+44 (0) 7901 514121

[Graham.mullis@novacyt.co.uk](mailto:Graham.mullis@novacyt.co.uk)